<DOC>
	<DOCNO>NCT00001863</DOCNO>
	<brief_summary>This study investigate safety effectiveness drug Leflunomide treat uveitis-an inflammation eye cause immune system abnormality . Leflunomide suppress immune system activity show control autoimmune disease , arthritis ( joint inflammation ) , animal . It also improve symptom patient rheumatoid arthritis , Food Drug Administration approve treat patient disease . Eye joint inflammation may similar cause , medicine arthritis often help patient eye inflammation . This study examine whether Leflunomide help patient uveitis . Patients uveitis respond well steroid treatment patient side effect medicine use treat uveitis ( cyclosporine , cyclophosphamide , methotrexate azathioprine ) refuse treatment possible side effect medicine may eligible study . Candidates screen medical history , physical examination , blood test eye examination . The eye exam include check vision eye pressure , examination back eye ( retina ) ophthalmoscope front eye microscope . They also undergo procedure call fluorescein angiography look blood vessel eye . A dye call sodium fluorescein inject bloodstream vein . After dye reach blood vessel eye , photograph take retina . Study participant divide two group . One group take 100 milligram Leflunomide day 3 day 20 milligram day 6 month . The group take placebo-a pill look like Leflunomide pill contain medicine . All patient group also take prednisone . Patients follow-up examination week 1 , 4 , 8 , 12 , 16 , 24 ( 6 month ) study . Each follow-up visit include repeat screen exams evaluation side effect discomfort medicine . Those well want continue assign treatment 6 month continue treatment another 6 month follow-up exams month 9 12 .</brief_summary>
	<brief_title>Leflunomide Treat Uveitis</brief_title>
	<detailed_description>Although corticosteroid remain mainstay therapy intraocular inflammation , many patient intolerant resistant corticosteroid therapy . In patient , immunosuppressive agent employ control potentially sight-threatening uveitis . Nevertheless , ideal therapy patient remain elusive , need new immunosuppressive agent vary mode action side effect profile . Leflunomide , isoxazole derivative , profound immunosuppressive activity . Leflunomide inhibit autoimmune disease animal model use treat patient rheumatoid arthritis ( RA ) . We propose randomize masked pilot trial leflunomide versus placebo treatment uveitis . Sixteen patient 16 year age older active intermediate , posterior , panuveitis randomly assign receive prednisone leflunomide prednisone placebo . Patients prednisone taper accord standardized schedule . The primary purpose study investigate safety efficacy leflunomide versus placebo . The primary safety endpoint frequency follow : abdominal pain , diarrhea , skin rash , hypertension , alopecia . In addition , weight loss distribution change liver function test describe . The primary efficacy endpoint one following ( 1 ) decrease 10 letter visual acuity baseline score reason , ( 2 ) inability taper prednisone 10 mg qd week 16 post randomization , ( 3 ) inability maintain prednisone taper Month 6 Month 12 , ( 4 ) addition systemic therapy treat ocular inflammatory disease . Secondary outcome include change vitreous haze presence absence cystoid macular edema .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis current intermediate posterior uveitis , panuveitis . Current evidence active intraocular inflammation base presence vitreous haze , active retinal lesion , retinal vasculitis , cystoid macular edema . 16 year age old . Visual acuity 73 letter few ( Snellen equivalent : 20/40 bad ) least one eye . The ability understand sign inform consent form must obtain prior randomization . The diagnosis intermediate uveitis require presence vitritis either peripheral retinal vascular disease , cellular debris inferior vitreous ( vitreous snowball ) , exudate par plana , peripheral retinal infiltrates . The diagnosis posterior uveitis require presence infiltrative retinal lesion involve posterior pole eye , usually vitritis often time cystoid macular edema . The amount cystoid macular edema grade standard protocol use Fluorescein Angiogram . The diagnosis panuveitis require find active anterior segment inflammation , vitritis , infiltrative retinal lesion . EXCLUSION CRITERIA : Ocular systemic disease require great 1 mg/kg/day prednisone great 80 mg qd patient weigh 80 kg , require systemic immunosuppressant . Periocular injection corticosteroid within previous 4 week . Intolerance contraindication corticosteroid . Female pregnant lactating . Patient refuse use contraception study 24 month termination active study therapy undergo cholestyramine washout regimen activate charcoal regimen care physician follow termination study therapy , childbearing father potential exists . Patients Behcet 's disease . Use Latanoprost within 2 week prior enrollment , current likely need Latanoprost course study . Hypersensitivity fluorescein dye . Contraindications use steroid dose schedule . SGOT ( AST ) SGPT ( ALT ) great equal 2 time upper limit normal . Allergic hypersensitivity leflunomide excipients .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Eye</keyword>
	<keyword>Vision</keyword>
	<keyword>Medication</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Leflunomide</keyword>
	<keyword>Vitritis</keyword>
</DOC>